ProLung’s mission is to improve outcomes for potential lung cancer patients through early predictive technologies, provide cost savings to patients, payers, and providers, and to provide a fair return on investment to […]
Alexandra Barnes
Fusion Genomics Advances Molecular Diagnostics
Fusion Genomics is a company that is working to advance molecular diagnostics through developing tests for pathogens that cause disease. They do this using proprietary technologies in combination with Next Generation Sequencing. […]
TapImmune Announces Fully-Funded Phase 2 Breast Cancer Vaccine Study
TapImmune, a clinical-stage immuno-oncology company developing peptide and gene-based immunotherapeutics for cancer and metastatic disease, announced the receipt of a $3.7 million grant from the U.S. Department of Defense (DoD). The grant […]
Interpace’s Molecular Tests Improve Diagnoses for Cancer Patients
Interpace Diagnostics is a company focused on the development and commercialization of molecular diagnostic tests aimed to optimize patient diagnosis and management. The company currently has three commercialized molecular tests: (1) PancraGen, […]
Biocept’s Liquid Biopsy Improves Cancer Treatment
Biocept is a diagnostic company that focuses on developing solutions aimed to optimize outcomes for cancer patients. Their most recent diagnostic comes in the form of a liquid biopsy, developed in an […]
Pieris’ Anticalin-Based Drugs Target Cancer, Asthma & Anemia
Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company in Boston, is developing Anticalin-based drugs for the treatment of cancer, asthma, anemia and other conditions that show a high unmet medical need. Pieris’ […]
ITUS’ Blood Test Detects Early Forms of Solid Tumor Based Cancers
ITUS Corporation is an early cancer detection technology company currently developing a platform called Cchek, a series of inexpensive, non-invasive blood tests for the early detection of cancer. Specifically, the test will […]
Dr. Christopher Schaber – President and CEO of Soligenix
Dr. Christopher Schaber is the President and CEO of Soligenix, a late stage biopharmaceutical company with a pipeline of pharmaceutical products to treat a variety of rare diseases with an unmet […]
